Li Minhua, Zheng Weiping, Wei Jianguo, Hou Chuanling, Yang Ye, Sun Liping, Wang Cheng
Department of Pathology, Shaoxing People's Hospital & Shaoxing Hospital of Zhejiang University, Shaoxing, China.
Department of Gynecology, Shaoxing People's Hospital & Shaoxing Hospital of Zhejiang University, Shaoxing, China.
Pathol Res Pract. 2017 Sep;213(9):1054-1058. doi: 10.1016/j.prp.2017.07.030. Epub 2017 Aug 1.
Thyroid transcription factor-1 (TTF-1) expression is widely considered a specific marker for lung and thyroid carcinomas and plays an important role in angiogenesis in lung cancer. However, it can occasionally be expressed in other malignancies, including ovarian carcinomas, and the mechanism of TTF-1 in lymphatic metastasis of ovarian carcinomas is still unclear. This study aimed to define the TTF-1 expression and lymph vessel density (LVD) in ovarian carcinomas and look for their correlations with clinicopathological features.
We examined the incidence of thyroid transcription factor 1 expression (clone SPT24) and lymph vessel density (LVD) quantified through D2-40 by immunohistochemistry from 110 primary ovarian carcinomas and 40 benign ovarian tumor as controls in Chinese patients.
Thyroid transcription factor 1 was detected in 28 primary ovarian carcinomas (25.5%), which was significantly higher than its expression in benign ovarian tumor. TTF-1 expression was correlated with tumor FIGO stage,T stage and lymphatic metastasis. Moreover, LVD was associated with tumor FIGO stage, TNM stage. Furthermore, the LVD counts in group of TTF-1 positive expression were higher than in group of TTF-1 negative expression.
These findings indicated the occasional expression of TTF-1 immunoreactivity of ovarian carcinomas should be considered in the evaluation of neoplasms of unknown primary origin and TTF-1 might be involved in lymph node metastasis of ovarian carcinomas in the presence of lymphangiogenesis.
甲状腺转录因子-1(TTF-1)表达被广泛认为是肺癌和甲状腺癌的特异性标志物,在肺癌血管生成中起重要作用。然而,它偶尔也可在包括卵巢癌在内的其他恶性肿瘤中表达,TTF-1在卵巢癌淋巴转移中的机制仍不清楚。本研究旨在明确卵巢癌中TTF-1的表达及淋巴管密度(LVD),并寻找它们与临床病理特征的相关性。
我们通过免疫组化检测了110例原发性卵巢癌患者及40例作为对照的良性卵巢肿瘤患者甲状腺转录因子1表达(克隆号SPT24)的发生率,并通过D2-40对淋巴管密度进行定量分析。
28例原发性卵巢癌(25.5%)检测到甲状腺转录因子1,其表达显著高于良性卵巢肿瘤。TTF-1表达与肿瘤国际妇产科联盟(FIGO)分期、T分期及淋巴转移相关。此外,LVD与肿瘤FIGO分期、TNM分期相关。而且,TTF-1阳性表达组的LVD计数高于TTF-1阴性表达组。
这些发现表明,在评估原发灶不明的肿瘤时应考虑卵巢癌TTF-1免疫反应性的偶尔表达,并且在存在淋巴管生成的情况下,TTF-1可能参与卵巢癌的淋巴结转移。